Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pioglitazone as add-on therapy in CP-CML
2009-011675-79Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone in chronic myelogenous leukemia (CML), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Complete molecular response rate at 24 weeks. Started Apr 2009; status: completed.
02
Drugs
pioglitazone
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2009-011675-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011675-79.